Oncology leads development in promising gene therapy pipeline

Despite few products having so far reached the market and captured strong revenues, the gene therapy pipeline remains large, with 906 products in active development across all stages


(Photo Courtesy: www.smanewstoday.com)

However, the majority of these remain in early steps of development, with 76% at either the discovery or preclinical stage, according to business intelligence provider GBI Research.

The company's latest report states that oncology, infectious diseases, genetic disorders, cardiovascular diseases and ophthalmological indications are the most active pipeline sectors, as well as the most widely studied in terms of the number of clinical trials.

There are 266 pipeline gene therapies in active development for oncology, more than double that of central nervous system disorders, which is the second-largest therapy area.

Furthermore, oncology also accounted for 64% of gene therapy clinical trials between 1989 and 2012.

Mr Dominic Trewartha, managing analyst, GBI Research, says: "Oncology is the predominant area for gene therapy developments due to its high prevalence and genetically driven pathophysiology.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email